LLY News and Press, Eli Lilly and Company From 12/22/23

2023-12-22 07:15:00 ET Every major biopharma business is staking out territory to take advantage of the artificial intelligence (AI) gold rush. Amid a mishmash of strategies -- like forging partnerships with innovative software companies and biotechs, acquiring promising players, and develo...

2023-12-21 17:34:44 ET Summary Eli Lilly and Company has had a strong year, and famed investor Ken Langone predicted it will become the first drug company to reach a market cap of $1 trillion. The obesity drug market for GLP-1s is estimated to add up to $15 billion in additional s...

2023-12-21 15:26:31 ET Summary Today, we look at generic drug concern Amphastar Pharmaceuticals, Inc., whose stock has more than doubled over the past year. The company also made a major acquisition this spring, but insider selling did pick up in November. What's ahead for Amp...

2023-12-21 09:45:00 ET The anti-obesity drug market could be worth $100 billion by 2030, according to analysts from Goldman Sachs . It's a mammoth market and one that looks to be heating up with a growing number of large healthcare companies showing interest in the space. Below, I'll lo...

2023-12-21 09:34:00 ET Summary Elanco Animal Health has faced revenue declines and suffered from high debt, creating a challenging operating environment. The company's performance has been disappointing, with missed synergy targets and declining sales. However, recent quarters...

2023-12-21 07:30:17 ET Summary Vanguard ESG U.S. Stock ETF follows an environmental, social, and corporate governance (“ESG”) approach. The sector breakdown is close to the S&P 500 index, but valuation and growth metrics are slightly inferior. While ESGV has ...

2023-12-20 21:46:55 ET Summary The Health Care Select Sector SPDR® Fund ETF has historically outperformed the S&P 500 with lower volatility. The ETF has underperformed this year, potentially due to the strong performance of the tech sector. Consensus estimates suggest...

2023-12-20 13:46:26 ET Summary Pfizer's stock reached an all-time high in 2021 due to high demand for its COVID-19 vaccine but has since declined by 45% year-to-date. The company has revised its financial guidance for FY24, expecting significantly lower sales and profits. Decl...

2023-12-20 09:30:00 ET Growth stocks have done well this year, but heading into 2024, many of them could start to lose steam, especially amid rising valuations. Yet, some businesses still look poised for much more growth in the years ahead, and are likely to continue rising in value next ye...

2023-12-20 08:30:00 ET Summary Point Biopharma and Lantheus Holdings released positive topline results for their radioligand therapy in patients with metastatic castration-resistant prostate cancer. The SPLASH trial met its primary endpoint, showing a progression-free survival ben...